NCT00002044已完成不适用
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
Glaxo Wellcome2 个研究点 分布在 1 个国家开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 试验地点
- 2
研究概览
简要总结
The purpose of this pilot study is to evaluate the efficacy of Retrovir (AZT) in the treatment of AIDS-related dementia and various neuromuscular complications. HIV is both a lymphotropic and neurotropic virus which can affect both the central and peripheral nervous systems (CNS, PNS). There is evidence that the CNS and PNS may harbor the virus in a latent state, with the potential for continuous reinfection of other body systems. Therefore, effective therapeutic efforts against HIV infection should provide effective antiviral activity within the nervous system.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Co-existing Condition:
- •Patients with the following are excluded:
- •Past or present renal disease.
- •Significant bone marrow suppression.
- •Blood transfusion within the past month.
- •Liver dysfunction.
- •Evidence of an underlying, severe infection.
- •Evidence of an active life-threatening opportunistic infection at study entry.
- •Severe malabsorption (patients with recent significant weight loss must have a serum carotene level of > 75 IU/ml).
- •Evidence of nervous system dysfunction being caused by factors other than HIV infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis, chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive multifocal leukoencephalopathy.
- •Other known causes of nerve or muscle disease.
- •Hypersensitivity to zidovudine (AZT).
- •Lymphoma or other tumor requiring cytotoxic chemotherapy.
- •Concurrent Treatment:
- •Electron beam therapy to an area of less than 100 cm
- •Patients with the following are excluded:
- •Past or present renal disease.
- •Significant bone marrow suppression.
- •Blood transfusion within the past month.
- •Liver dysfunction.
- •Evidence of an underlying, severe infection.
- •Evidence of an active life-threatening opportunistic infection at study entry.
- •Severe malabsorption (patients with recent significant weight loss must have a serum carotene level of > 75 IU/ml).
- •Evidence of nervous system dysfunction being caused by factors other than HIV infection, particularly by cerebral toxoplasmosis, lymphoma, cryptococcal meningitis, chronic alcohol abuse, lead poisoning, cytomegalovirus (CMV) infection (patients with retinal CMV infection or other evidence of CMV dementia), syphilis, or progressive multifocal leukoencephalopathy.
- •Other known causes of nerve or muscle disease.
- •Hypersensitivity to zidovudine (AZT).
- •Lymphoma or other tumor requiring cytotoxic chemotherapy.
- •Patients with AIDS (CDC surveillance definition) or AIDS related complex (ARC).
- •All patients must have either:
- •Dementia as defined by a progressive cognitive impairment in the absence of altered consciousness that is thought to be causally related to HIV infection. Patients in this study will fall into the lower 20 percent (or less) of a normal sample of formal neuropsychological testing.
- •One of the following neuromuscular diseases thought to be related to HIV infection:
- •Demyelinating polyneuropathy, axonal polyneuropathy, inflammatory myopathy, or unexplained progressive muscle weakness.
- •Capacity to give informed consent or a person with durable power of attorney who can give informed consent.
- •Life expectancy = or > 4 months.
排除标准
- •Concurrent Medication:
- •Cytotoxic chemotherapy.
- •Steroids.
- •Interferon.
- •Immunomodulating agents.
- •Concurrent Treatment:
- •Radiation therapy (except electron beam therapy to an area of less than 100 cm2).
- •Prior Medication:
- •Excluded within 4 weeks of study entry:
- •Cytotoxic chemotherapy.
- •Any retroviral drug including but not limited to zidovudine (AZT), ribavirin, HPA 23, AL721, or phosphonoformate.
- •Steroids.
- •Interferon.
- •Immunomodulating agents.
- •An anticipated need for any of these agents within the next 16 weeks.
- •Prior Treatment:
- •Excluded within 1 month of study entry:
- •Radiation therapy (except electron beam therapy to an area of less than 100 cm2).
- •Blood transfusion.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A Study of Retrovir in the Prevention of HIV Infection in Health Care Workers Accidentally Exposed to the VirusHIV InfectionsNCT00002287Glaxo Wellcome
已完成
2 期
A Pilot Study of the Immunologic Reconstitution in HIV-1 Infected Children Receiving Highly Active Antiretroviral Therapy With Combination Ritonavir, Nevirapine and StavudineHIV InfectionNCT00001688National Cancer Institute (NCI)25
已完成
3 期
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a InfectionChronic Hepatitis C InfectionNCT01833533AbbVie305
已完成
3 期
A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b InfectionChronic Hepatitis C InfectionNCT01767116AbbVie (prior sponsor, Abbott)419
已完成
2 期
Measure of Pharmacokinetic Parameters and Adherence With MEMS in Naive HIV Infected Patients Treated With Reyataz Once Daily Combined With Norvir and TruvadaHIV InfectionsNCT00528060French National Agency for Research on AIDS and Viral Hepatitis35